2-hydroxy-1-(pyridin-2-yl)butan-1-one | 110124-57-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-hydroxy-1-(pyridin-2-yl)butan-1-one
• 英文别名: 2-hydroxy-1-(2-pyridyl)butan-1-one；2-hydroxy-1-pyridin-2-ylbutan-1-one
• CAS: 110124-57-7
• 化学式: C₉H₁₁NO₂
• 分子量: 165.192
• InChiKey: CXRNZBWAZIIIFA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-hydroxy-1-(pyridin-2-yl)butan-1-one 、 碳酸氢钠 以 盐酸 、 水 为溶剂， 生成 5-Ethyl-4-(pyridin-2-yl)-2(3H)-oxazolone
  参考文献：
  名称：

  Cardiotonic heterocyclic oxazolones

  摘要：

  杂环噁唑酮可以增强心肌收缩力和心脏功能，并被用作心力衰竭的心脏强心剂。

  公开号：

  US04698353A1

文献信息

• Inhibition of metastasis in patients having cancer with
  申请人：Merrell Pharmaceuticals Inc.

  公开号：US05610171A1

  公开（公告）日：1997-03-11

  This invention is directed to pyridinyloxazole-2-ones which are useful in inhibiting metastasis in patients having cancer. The pyridinyloxazole-2-ones act to inhibit protein kinase C and thereby modulate metastasis in patients having cancer.

  这项发明涉及对于患有癌症的患者有用的吡啶氧唑-2-酮，可以用于抑制转移。这些吡啶氧唑-2-酮通过抑制蛋白激酶C来调节患有癌症的患者的转移。
• Treatment of multi-drug resistant tumors with pyridyloxazole-2-ones
  申请人：Merrell Dow Pharmaceuticals Inc.

  公开号：US05182293A1

  公开（公告）日：1993-01-26

  This invention relates to pyridinyloxazole-2-ones which are useful in the treatment of multi-drug resistant tumors. The pyridinyloxazole-2-ones act to prevent drug resistance and thus allow conventional chemotherapeutic agents to kill tumor cells as if drug resistance were not present.

  本发明涉及吡啶氧唑-2-酮，其在治疗多药耐药肿瘤方面非常有用。这些吡啶氧唑-2-酮具有防止药物耐药性的作用，因此可以使传统化疗药物能够像不存在药物耐药性一样杀死肿瘤细胞。
• Prevention of glycoprotein enveloped virus infectivity by
  申请人：Merrell Dow Pharmaceuticals Inc.

  公开号：US05063238A1

  公开（公告）日：1991-11-05

  This invention relates to pyridinyloxazole-2-ones which are useful anti-enveloped virus agents by virtue of their ability to act as protein kinase C inhibitors. These derivatives are disclosed to be effective in treating enveloped virus infections including HIV infections and are thus useful in the treatment of AIDS and ARC.

  本发明涉及吡啶氧唑-2-酮，其具有作为蛋白激酶C抑制剂的能力，因此是有用的抗包膜病毒药物。这些衍生物被披露为有效治疗包膜病毒感染，包括HIV感染，因此在治疗艾滋病和ARC方面是有用的。
• Novel pyridyloxazole 2-ones useful as proteinkinase C inhibitors
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0428106A1

  公开（公告）日：1991-05-22

  This invention relates to novel pyridyloxazole-2-ones which are useful as protein kinase C inhibitors, effective in the treatment of hypertension and asthma.

  本发明涉及新型吡啶恶唑-2-酮，可用作蛋白激酶 C 抑制剂，有效治疗高血压和哮喘。
• Prevention of glycoprotein enveloped virus infectivity by pyridyloxazole-2-ones
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0428103A2

  公开（公告）日：1991-05-22

  This invention relates to pyridinyloxazole-2-ones which are useful anti-enveloped virus agents by virtue of their ability to act as protein kinase C inhibitors. These derivatives are disclosed to be effective in treating enveloped virus infections including HIV infections and are thus useful in the treatment of AIDS and ARC.

  本发明涉及吡啶并噁唑-2-酮，由于它们能够作为蛋白激酶 C 抑制剂而成为有用的抗包膜病毒制剂。据披露，这些衍生物可有效治疗包膜病毒感染，包括艾滋病病毒感染，因此可用于治疗艾滋病和 ARC。